技術資料

RTECS ファイル - 回答レコードの見方

● レコード中に使用されている略語一覧

The following list is a key to abbreviations used in the RTECS File:

ACGIH American Conference of Govermental Industrial Hygenists
C continuous
cc cubic centimeter
CL ceiling concentration
CRIT DOC NIOSH criteria document
D day
DEF definition
DOT Department of Transportation
EPA Environmental Protection Agency
fb fiber
gm gram
H hour
I intermittent
IARC International Agency for Research on Cancer
kg kilogram (one thousand grams)
L liter
LC50 lethal concentration 50 percent kill
LCLo lowest published lethal concentration
LD50 lethal dose 50 percent kill
LDLo lowest published lethal dose
M minute
m3 cubic meter
mg milligram (one thousandth or a gram; 10-3 grams)
MGN multigeneration
ml milliliter
mmol millimole
mol mole
mppcf million particles per cubic foot
mul multiple routes
ng nanogram (one billionth of a gram; 10-9 grams)
nmol nanomole
nse non-standard exposure
OBS obsolete (trade name)
OEL Occupational Exposure Limit
ORM Other Regulated Material (DOT)
OSHA Occupational Safety and Health Administration
pg picogram (one trillionth of a gram; 10-12 grams)
Pk peak concentration
pmol picomole
post after birth
ppb parts per billion (v/v)
pph parts per hundred (v/v) (percent)
ppm parts per million (v/v)
ppt parts per trillion (v/v)
pre prior to copulation
preg pregnant
REGS standards and regulations
rns rinsed with water
RTECS Registry of Toxic Effects of Chemical Substances
SCP Standards Completion Program
S second
STEL Short Term Exposure Limit
TLV Threshold Limit Value
TC toxic concentration
TCLo lowest published toxic concentration
TD toxic dose
TDLo lowest published toxic dose
TLV Threshold Limit Value
TWA time weighted average
ug microgram (one millionth of a gram; 10-6 grams)
umol micromole
USOS U.S. Occupational Health Standard
W week
Y year
% percent

● Toxic Effects Codes (/EFF)

The following Toxic Effects Codes are used in the RTECS File:

A Brain and Coverings
B Spinal Cord
C Peripheral Nerve Sensation
D Sense Organs and Special Senses
E Autonomic
F Behavioral
G Cardiac
H Vascular
I Aquatic Organism Effects
J Lung, Thorax, or Respiration
K Gastrointestinal
L Liver
M Kidney, Ureter, and Bladder
N Endocrine
P Blood
Q Musculoskeletal
R Skin and Appendages
S Immunologic including Allergic
T Reproductive including Embryotoxic, Neonatal and Teratogenic
U Nutritional and Gross Metabolic
V Tumorigenic
X In Vitro Toxicity Studies
Y Biologic
Z Related to Chronic Data

----------------------------------------------------
--------------------------
A Brain and Coverings

Damage Codes

01 Meningeal changes
02 Changes in cerebral spinal fluid
03 Increased intracranial pressure
04 Changes in circulation (hemorrhage, thrombosis, etc.)
05 Encephalitis
06 Demyelination
10 Changes in surface EEG
11 Recordings from specific areas of CNS
30 Other degenerative changes
60 Tumors
70 Changes in brain weight


B Spinal Cord

Damage Codes

01 Meningeal changes
02 Changes in circulation
03 Inflammatory changes
04 Demyelination
30 Other degenerative changes
60 Tumors


C Peripheral Nerve Sensation

Damage Codes

01 Associated connective tissue
02 Sensory syndrome diagnostic of central lesion
03 Sensory change involving trigeminal nerve
04 Sensory change involving peripheral nerve
05 Sensory change involving segmental distribution
06 Spastic paralysis with or without sensory change
07 Flaccid paralysis with appropriate anesthesia
08 Flaccid paralysis without anesthesia (usually
neuromuscular blockage)
09 Fasciculations
10 Paresthesia
15 Recording from afferent nerve
16 Recording from peripheral motor nerve
17 Local anesthetic
18 Structural change in nerve or sheath
60 Tumors


D Sense Organs and Special Senses (nose, eye, ear, and taste)

Damage Codes

Olfaction:

01 Deviated nasal septum
02 Ulcerated nasal septum
03 Change in olfactory nerve
04 Change in sensation of smell
07 Other
09 Tumors

Eye:

10 Optic nerve neuropathy
11 Cycloplegia
12 Changes in refraction
13 Ciliary spasm
14 Visual field changes
15 Miosis (pupilliary constriction)
16 Mydriasis (pupilliary dilation)
17 Lacrimation
18 Chromidracryorrhea
19 Increased intraocular pressure
20 Retinal changes (pigmentary deposition, retinitis,
other)
21 Hemorrhage
22 Changes in circulation
23 Diplopia
24 Changes in extra-ocular muscles
25 Conjunctive irritation
26 Corneal damage
27 Iritis
28 Ptosis
29 Tumors
35 Other

Ear:

40 Change in acuity
41 Tinnitus
43 Changes in vestibular functions
44 Changes in cochlear structure or function
45 Tumors

Taste:

50 Change in function

E Autonomic Nervous System

Damage Codes

01 Sympathomimetic
02 Alpha adrenergic blocker
03 Beta adrenergic blocker
04 Central sympatholytic
05 Ganglion blocker
06 Ganglion facilitant
08 Other (direct) parasympathomimetic
09 Intensity beta adrenergic effects
15 Smooth muscle relaxant (mechanism undefined,
spasmolytic)
16 Parasympatholytic

F BEHAVIORAL

Damage Codes

01 General anesthetic
02 Anticonvulsant
03 Wakefulness
04 Sleep
05 Altered sleep time (including change in righting
reflex)
06 Euphoria
07 Somnolence (general depressed activity)
08 Hallucinations, distorted perceptions
09 Changes in REM sleep (human)
10 Toxic psychosis
11 Tremor
12 Convulsions or effect on seizure threshold
13 Excitement
14 Anorexia (human)
15 Food intake (animal)
16 Fluid intake
17 Change in motor activity (specific assay)
18 Muscle weakness
19 Ataxia
20 Stiffness
21 Rigidity (includes catalepsy)
22 Tetany
23 Muscle contraction or spasticity
24 Coma
25 Antipsychotic
26 Antianxiety
27 Headache
29 Analgesia
30 Tolerance
31 Withdrawal
32 Abuse
33 Irritability
34 Straub tail reaction
40 Alteration of classical conditioning
41 Alteration of operant conditioning
42 Change in psychophysiological tests
43 Aggression


G CARDIAC

Damage Codes

01 Cardiomyopathy including infarction
02 Changes in coronary arteries
03 Pericarditis
04 Arrythmias (including changes in conduction)
05 Cardiomegaly
06 EKG changes not diagnostic of above
07 Pulse rate increased without fall in BP
08 Pulse rate
09 Change in force of contraction
10 Change in rate
11 Change in conduction velocity
12 Cardiac output
13 Change in resting or action potential
30 Other changes
60 Tumors
70 Changes in heart weight


H Vascular

Damage Codes

01 BP Elevation not characterized in autonomic section
02 BP lowering not characterized in autonomic section
03 Pulse pressure increase
04 Regional or general arteriolar constriction
05 Regional or general arteriolar or venous dilation
06 Measurement of regional blood flow
07 Change in plasma or blood volume
08 Shock
15 Acute arterial occlusion
16 Structural changes in vessels
17 Thrombosis distant from injection site
20 Contraction (isolated tissues)
21 Relaxation (isolated tissues)
30 Other changes
35 Effect on gills and gill functions
60 Tumors


I Aquatic Organism Effects

Damage Codes

01 Maturation delay
02 Growth retardation


J Lungs, Thorax, or Respiration

Damage Codes

01 Ciliary function changes
02 Structural or functional change in trachea or bronchi
03 Bronchiolar dilation
04 Bronchiolar constriction
05 Bronchiectasis
06 Emphysema
07 Changes in pulmonary vascular resistance
08 Consolidation
12 Fibrosis, focal (pneumoconiosis)
13 Fibrosis, interstitial
14 Fibrosing alveolitis
15 Acute pulmonary edema
16 Chronic pulmonary edema
17 Pleural effusion
18 Pleural thickening
20 Respiratory obstruction
21 Cough
22 Dyspnea
23 Sputum
24 Cyanosis
25 Respiratory depression
26 Respiratory stimulation
27 Pulmonary emboli
30 Other changes
60 Tumors
61 Bronchiogenic carcinoma
70 Changes in lung weight


K Gastrointestinal

Damage Codes

01 Changes in structure or function of salivary glands
02 Changes in structure or function of exocrine pancreas
03 Changes in structure or function of esophagus
04 Alteration in gastric secretion
05 Gastritis
06 Ulceration or bleeding from stomach
07 Ulceration or bleeding from duodenum
08 Ulceration or bleeding from small intestine
09 Ulceration or bleeding from large intestine
12 Hypermotility, diarrhea
13 Nausea or vomiting
14 Decreased motility or constipation
15 Malabsorption
17 Peritonitis
20 Necrotic changes
30 Other changes
31 Contraction (isolated tissue)
32 Relaxation (isolated tissue)
60 Tumors
61 Colon tumors
70 Changes in pancreatic weight


L Liver

Damage Codes

01 Hepatitis (hepatocellular necrosis), diffuse
02 Hepatitis (hepatocellular necrosis), zonal
03 Fatty liver degeneration
04 Hepatitis, fibrous (cirrhosis, post-necrotic
scarring)
11 Jaundice, cholestatic
12 Jaundice, other or unclassified
14 Liver function tests impaired
15 Change in gall bladder structure or function
19 Jaundice (or hyperbilirubinemia) hepatocellular
30 Other changes
50 Multiple effects
60 Tumors
61 Angiosarcoma
70 Changes in liver weight


M Kidney, Ureter, and Bladder

Damage Codes

01 Changes in blood vessels or in circulation of kidney
02 Changes primarily in glomeruli
03 Changes in tubules (including acute renal failure,
acute tubular necrosis)
04 Changes in both tubules and glomeruli
05 Interstitial nephritis
10 Urine volume increased
11 Urine volume decreased
12 Renal function tests depressed
13 Proteinuria
14 Hematuria
16 Other changes in urine composition
20 Inflammation, necrosis, or scarring of bladder
21 Structural or functional changes in ureter
29 Incontenance
30 Other changes
60 Tumors
61 Kidney tumors
70 Chenges in bladder weitht
71 Changes in kidney weight


N Endocrine

Damage Codes

01 Antidiruesis
02 Change in LH
03 Change in GH
04 Change in gonadotropins
05 Thyroid weight (goiter)
06 Toxic goiter-hypofunction
07 Evidence of thyroid hyperfunction
08 Evidence of thyroid hypofunction
10 Hyperparathyroidism
12 Adrenal cortex hyperplasia
13 Adrenal cortex hypoplasia
15 Aldosternism
16 Androgenic
17 Estrogenic
18 Differential effect of sex or castration on observed
toxicity
19 Effect on menstrual cycle
20 Gynecomastia
21 Diabetes mellitus
22 Hypoglycemia
23 Ketosis
24 Hyperglycemia
25 Diabetes Insipidus (nephrogenic or CNS)
30 Other changes
60 Tumors
61 Adrenal cortex tumors
62 Thyroid tumors
70 Changes in endocrine weight (unspecified)
71 Changes in pituitary weight
72 Changes in adrenal weitht
73 Changes in spleen weight
74 Changes in thymus weight
75 Changes in thyroid weight


P Blood

Damage Codes

01 Hemorrhage
02 Change in clotting factors
05 Normocytic anemia
06 Microcytosis with or without anemia
07 Macrocytosis
08 Pigmented or nucleated red blood cells
13 Granulocytopenia
14 Leukopenia
15 Agranulocytosis
16 Eosinophilia
17 Thrombocytopenia
20 Changes in cell count (unspecified)
22 Oxidant related (GPD deficient) anemia
23 Other hemolysis with or without anemia
24 Methemoglobinemia-Carboxyhemoglobin
25 Aplastic anemia
26 Changes in bone marrow not included above
27 Changes in spleen
28 Changes in serum composition
30 Other changes
60 Tumors
61 Leukemia
62 Lymphomas including Hodgkin's disease
70 Changes in other cell count (unspecified)
71 Changes in erythrocyte (RBC) cell count
72 Changes in leucocyte (WBC) cell count
73 Changes in platelet cell count


Q Musculoskeletal (See also Behavioral (F) for muscle changes secondary to CNS or metabolic changes)

Damage Codes

01 Changes in teeth and supporting structures
02 Osteoporosis
10 Osteomalacia
15 Joints
30 Other changes
60 Tumors


R Skin and Appendages

Damage Codes

Skin:

After systemic exposure:
01 Dermatitis, allergic
02 Dermatitis, irritative
03 Dermatitis, other
04 Photosensitivity

After topical application:
10 Primary irritation
11 Corrosive
12 Dermatitis, allergic
13 Cutaneous sensitization (experimental)
14 Photosensitivity

Other:
20 Sweating
21 Hair
22 Nails
25 Breast
30 Other glands
60 Tumors


S Immunological including Allergic

Damage Codes

01 Increase in cellular immune response
02 Decrease in cellular immune response
03 Increase in humoral immune response
04 Decrease in humoral immune response
05 Decreased immune response
06 Increased immune response

Allergic (Multiple organ involvement)

When single organs are involved, the code is under the organ.
Cholestatic jaundice - see Liver (L)
Aplastic anemia, agranulocytoses - see Blood (P)
Allergic dermatitis - see Skin (R)

15 Anaphylaxis
16 Other immediate (humoral): urticaria, allergic
rhinitis, serum sickness
18 Hypersensitivity delayed
20 Autoimmune
25 Uncharacterized


T Reproductive including Embryotoxic, Neonatal and Teratogenic

Damage Codes

Paternal Effects:
O1 Spermatogenesis (including genetic material, sperm
morphology, motility, and count)
O2 Testes, epididymis, sperm duct
03 Prostate, seminal vessicle, Cowper's gland, accessory
glands
O4 Impotence
O5 Breast development
O9 Other effects on male

Maternal Effects:
11 Oogenesis
12 Ovaries, fallopian tubes
13 Uterus, cervix, vagina
14 Menstrual cycle changes or disorders
15 Breasts, lactation (prior to or during pregnancy)
16 Parturition
17 Postpartum
19 Other effects on females

Effects on Fertility:
21 Mating performance (e.g., number of sperm positive
females per number of females mated; number of
copulations per number of estrus cycles)
22 Female fertility index (e.g., number of females
pregnant per number of sperm positive females; number
of females pregnant per number of females mated)
23 Male fertility index (e.g., number of males
impregnating females per number of males exposed to
fertile nonpregnant females)
24 Pre-implantation mortality (e.g., reduction in number
of implants per female; total number of implants
per corpora lutea)
25 Post-implantation mortality (e.g., dead and/or
resorbed implants per total number of implants)
26 Litter size (e.g., number of fetuses per litter;
measured before birth)
27 Abortion
29 Other measures of fertility

Effects on Embryo or Fetus:
31 Extra embryonic structures (e.g., placenta, umbilical
cord)
32 Maternal-fetal exchange
33 Cytological changes (including somatic cell genetic
material)
34 Fetotoxicity (expect death, e.g., stunted fetus)
35 Fetal death
39 Other effects to embryo or fetus

Specific Developmental Abnormalities:
41 Central nervous system
42 Eye, ear
43 Craniofacial (including nose and tongue)
44 Skin and skin appendages
45 Body Wall
46 Musculoskeletal system
47 Cardiovascular (circulatory) system
48 Blood and lymphatic systems (including spleen and
marrow)
49 Respiratory system
50 Gastrointestinal system
51 Hepatobiliary system
52 Endocrine system
53 Urogenital system
54 Immune and reticuloendothelial system
55 Homeostatis
59 Other developmental abnormalities

Tumorigenic Effects:
61 Testicular tumors
62 Prostate tumors
63 Ovarian tumors
64 Uterine tumors
65 Transplacental tumorigenesis
69 Other reproductive system tumors

Effects on Newborn:
71 Stillbirth
72 Live birth index (similar to T26 , except measured
after birth)
73 Sex ratio
74 Apgor score (human only)
75 Viability index (e.g., number alive at day 4 per
number born alive)
76 Weaning or lactation index (e.g., number alive at
weaning per number alive at day 4)
77 Other neonatal measures or effects
81 Growth statistics (e.g., reduced weight gain)
82 Germ cell effects (in offspring)
83 Biochemical and metabolic
84 Drug dependence
85 Behavioral
86 Physical
87 Other postnatal measures or effects
91 Delayed effects


U Nutritional And Gross Metabolic

See also Biochemical [Metabolism - intermediary] (Y)

Damage Codes

01 Weight loss or decreased weight gain
02 Conditioned vitamin deficiency
03 Dehydration

Changes in:
05 Na
06 Cl
07 Ca
08 P
09 Fe
10 K
11 Other metals
20 Metabolic acidosis
21 Metabolic alkalosis
25 Body temperature increase
28 Body temperature decrease
30 Other changes


V TUMORIGENIC

Damage Codes

01 Carcinogenic by RTECS criteria
02 Neoplastic by RTECS criteria
03 Equivocal tumorigenic agent by RTECS criteria
05 Cells (cultured) transformed
08 Increased incidence of tumors in susceptible strains
10 Tumors at site of application
15 Tumor types after systemic administration not seen
spontaneously
16 Facilitates action of known carcinogens
25 Protects agains induction of experimental tumors
30 Active as anti-cancer agent


X In Vitro Toxicity Studies

Damage Codes

01 Cell counting
02 Cell viability (cell death), unspecified assay
03 Cell differentiation
04 Cell growth: colony formation
05 Cell membrane integrity: cytoplasmic enzymes leakage
(lactate dehydrogenase, ATP enzymes etc.)
06 Cell metabolic activity: Alamar Blue assay etc.
07 Cell morphology: overgrowth of cell appendixes etc.
08 Cell proliferation: DNA incorporation, mitotic index etc.
09 Cell viability (dye exclusion): trypan blue assay etc.
10 Cell viability (lysosomal damage): neutral red assay etc.
11 Cell viability (mitochondrial reductase assays): MTT,
XTT, MTS, WSTs assays etc.
12 Hemolysis in vitro
13 Cell protein synthesis
14 Apoptosis in vitro
15 Cell membrane integrity (prelabeled cells): release of
radioactive isotopes ([51Cr], [3H]-thymidine,
[3H]-proline, [35S]- or [75Se]-methionine,
5-[125I]-2-deoxy-uridine) or fluorescent dyes
(bis-carboxyethyl-carboxyfluorescein (BCECF) or
calcein-AM)
16 Membrane currents
17 Phototoxicity in vitro
30 Other assays


Y Biologic

Damage Codes

Enzyme inhibition, induction, or change in blood or tissue levels:
01 True cholinesterase
02 Other esterases
03 Phosphatases
04 Other hydrolases
05 Carbonic anhydrase
06 Xanthine oxidases
07 Hepatic microsomal mixed oxidase (dealkylation,
hydroxylation, etc.)
08 Monoamine oxidase
09 Cytochrome oxidases (including oxidative
phosphorylation)
10 Dehydrogenases
11 Catalases
12 Other oxidoreductases
13 Phosphokinase
14 Hexokinases
15 Transaminases
16 Other transferases
17 Peptidases
18 Proteases
19 Isomerases
20 Multiple enzyme effects
21 Other enzymes
23 Reactivates cholinesterase

Effect on specific coenzyme:
25 B vitamin including folate
26 CoA
27 NAD, NADP
28 Others
29 Proportion of isoenzymes
30 Disturbed regulation

Metabolism (intermediary):
35 Xanthine, purine, or nucleotides including urate
36 Porphyrin including bile pigments
37 Lipids including transport
38 Amino acids (including renal excretion)
39 Plasma proteins not involving coagulation
40 Other proteins
41 Glycolytic
42 TCS cycle
43 Pentase shunt
44 Other carbohydrates
45 Histamines (including liberation not immunochemical
in origin)
50 Effect on mitochondrial function
51 Effect on active transport
52 Effect on Na-K pump
53 Other
54 Effect on cyclic nucleotides
55 Effect on inflammation or mediation of inflammation

Neurotransmitters or modulators (putative):

60 Catecholamine levels in sympathetic nerves
61 Catecholamine levels in CNS
64 Dopamine in striatum
65 Dopamine at other sites


Z RELATED TO CHRONIC DATA

Damage Codes

01 Death in the "U" type multiple dose data

Changes in:

71 Changes in Ovarian weight
72 Changes in Prostate weight
73 Changes in Testicular weight
74 Changes in Uterine weight


● 毒性に関するサンプルレコードとその見方

=> D TOX           ← 一般毒性データを表示する

L1 ANSWER 1 of 1 RTECS COPYRIGHT 2002 DOC TOXICITY DATA (TOX): 作用 経路 生物種 1) 投与量 2) 期間 出典情報 ↓ ↓ ↓ ↓ ↓ ↓ Effect | Route | Organism | Dose |Duration| Source EFF | RTE | ORGN | DOSE | DUR | SO ← フィールド ===========+===============+==========+===========+========+=========== コード 9) F07;F11;F24|oral |man |TDLo 1 | |TOSCF2 | | |mL/kg | |41,157,1998 -----------+---------------+----------+-----------+--------+----------- |oral |human   |LDLo 7 g/kg| |ARTODN | | | | |35,295,1976 -----------+---------------+----------+-----------+--------+----------- K30 |oral |man |TDLo 2143 | |34ZIAG | | |mg/kg | |-,602,1969 -----------+---------------+----------+-----------+--------+----------- F07;F08 |inhalation |human |TCLo 6900 |10M |AHBAAM | | |mg/m**3 | |116,131,1936 -----------+---------------+----------+-----------+--------+----------- : 省略 => E F07/EFF ← /EFF フィールドで コードを EXPAND するとコードが示す毒性の種類 E1 74 F06/EFF や程度が表示される E2 74 F06 (EUPHORIA)/EFF E3 9094 --> F07/EFF E4 9094 F07 (SOMNOLENCE)/EFF ← 傾眠 : 省略 E12 2821 F11 (TREMOR)/EFF

注 1)
人間に対する毒性データに関しては,できるだけ man,wmn (woman の略),child,infant などを付与しており,これ以外は human と表示されている.

注 2)
- LDLo
最低致死量 (Lethal Dose Low).投与量 (mg/kg) は /LDLO フィールドで数値検索できる.

- LD50
50%致死量 (Lethal Dose Fifty).投与量 (mg/kg) は /LD50 フィールドで数値検索できる.

- TDLo
最低毒性量 (Toxic Dose Low).投与量 (mg/kg) は /TDLO フィールドで数値検索できる.

- LCLo
最低致死濃度 (Lethal Concentration Low).投与量 (mg/m3 又は ppm) は /LCLOA 又は /LCLOVフィールドで数値検索できる.

- LC50
50%致死濃度 (Lethal Concentration Fifty).
投与量 (mg/m3 又は ppm) は/LC50A 又は /LC50V フィールドで数値検索できる.

- TCLo
最低毒性濃度 (Toxic Concentration Low).
投与量 (mg/m3 又は ppm) は /TCLOA 又は /TCLOV フィールドで数値検索できる.

● そのほかの毒性に関するサンプルレコードとその見方 (OMUL)

このフィールドには,様々な投与期間と投与量で化学物質の毒性を研究した結果が収録されている. 致死量ではなく,毒性が発現する程度の投与量の結果が収録されており,急性毒性結果の収録が多い TOX フィールドの内容とは異なる.

=> D OMUL     ← その他の毒性データを表示する

L1 ANSWER 1 of 1 RTECS COPYRIGHT 2002 DOC
OTHER MULTIPLE DOSE DATA (OMUL):
作用 経路 生物種 投与量 期間 出典情報 ↓ ↓ ↓ ↓ ↓ ↓ Effect | Route | Organism | Dose |Duration | Source EFF | RTE | ORGN | DOSE | DUR | SO ← フィールド ===========+===========+==========+==========+=========+=========== コード A06 |oral |rat |TDLo 1160 |8W-I |NETEEC | | |mg/kg | |12,375,1990 -----------+-----------+----------+----------+---------+----------- L70;M70;Y07|oral |rat |TDLo 84 |2W-C |TOXID9 | | |g/kg | |5,228,1985 -----------+-----------+----------+----------+---------+----------- : 省略

● 変異原性データに関するサンプルレコードとその見方

=> D MUT       ← 変異原性データを表示する
 
L1 ANSWER 1 of 1 RTECS COPYRIGHT 2002 DOC
MUTATION DATA (MUT):
試験方式 3) 生物種 4) 細胞種類 4) 経路 投与量 期間 出典情報 ↓ ↓ ↓ ↓ ↓ ↓ ↓ System | Organism |Cell Type | Route | Dose |Dur.| Source SYS | ORGN | CELL | RTE | DOSE |DUR | SO ===============+============+==========+==========+========+====+=========== mutation in |Salmonella | | |10 | |TECSDY microorganisms |typhimurium | | |ug/plate| |15,101,1987 | | | |(+/-S9) | | ---------------+------------+----------+----------+--------+----+----------- mutation in |Escherichia | | |3300 | |BCPCA6 microorganisms |coli | | |umol/L | |24,2013,1975 | | | |(+S9) | | ---------------+------------+----------+----------+--------+----+----------- : 省略

注 3)
変異原性を調べる試験方式は複数ある.現在このフィールドに含まれている試験方式は以下の通り.

  - Mutation in Microorganisms                    - Microsomal Assay
  - Micronucleus Test                             - Specific Locus Test
  - DNA Damage                                    - DNA Repair
  - Unscheduled DNA Synthesis                     - DNA Inhibition
  - Cytogenetic Analysis                          - Sister Chromatid Exchange
  - Sex Chromosome Loss and Nondisjunction
  - Gene Conversion and Mitotic Recombination
  - Other mutation test system (上記の方式以外)

注 4)
変異原性試験では,対象生物として動物単体の他に,微生物や動物の細胞も用いる.このため,他の試験データとは異なり細胞種類のフィールドが設けられている.

● 生殖試験データに関するサンプルレコードとその見方

=> D REP    ← 生殖試験データを表示する 
 
L1 ANSWER 1 of 1 RTECS COPYRIGHT 2002 DOC
REPRODUCTIVE EFFECTS DATA (REP):
作用 経路 5) 生物種 投与量 6) 期間 7) 出典情報 ↓ ↓ ↓ ↓ ↓ ↓ Effect | Route |Organism| Dose | Duration | Source EFF | RTE | ORGN | DOSE | DUR | SO =======+==========+========+=========+==============+============ T85 |oral |rat |TDLo 2688|1-22D preg/21D|TOXID9 | | |mg/kg |post |4,179,1984 -------+----------+--------+---------+--------------+------------ T76 |oral |rat |TDLo 36 |15D pre/1-21D |TXCYAC | | |g/kg |preg |32,229,1984 -------+----------+--------+---------+--------------+------------ : 省略

注 5)
両方の親に投与されておりしかも投与経路がそれぞれ異なる場合は multiple と表示される.

注 6)
投与された物質の総量

注 7)
生殖周期のどの時点で投与されているかによって,投与物質の効果は大きく左右される.
このため投与期間は生殖周期に基づいて表されている.基本的な表記方法は以下のとおり.

uD male/vD pre/w-xD preg/yD post

u:交配前の雄に投与した期間の総日数
v:交配前の雌に投与した期間の総日数
w:妊娠している雌に投与した最初の日
x:妊娠している雌に投与した最後の日
y:出産後,授乳期の雌に投与した期間の総日数

例) 1-22D preg/21D post:妊娠後 1日目から 22 日目までと,出産後授乳期中 21日間雌に投与.

● 催腫瘍性データに関するサンプルレコードとその見方

この他の催腫瘍性に関する情報は,癌レビュー (CREV) フィールド,限界値 (TLV) フィールドおよび機関識別 (ASTA) フィールドの NTP の項を参照.

=> D TUMFULL   ← 詳しい出典情報を含めた表示形式で,催腫瘍性データを表示する

L1 ANSWER 1 of 1 RTECS COPYRIGHT 2002 DOC
TUMORIGENIC DATA (TUM):
作用 経路 生物種 投与量 8) 期間 9) 出典情報 10) ↓ ↓ ↓ ↓ ↓ ↓ Effect | Route |Organism| Dose |Duration | Source EFF | RTE | ORGN | DOSE | DUR | SO ===========+==========+========+===========+=========+=========== V01;J60;R60|inhalation|rat |TCLo 150 |7H/2Y-I |INHEAO ← CODEN 10) | | |ppm | |21,243,1983 -----------+----------+--------+-----------+---------+----------- V01;L60 |oral |mouse |TDLo 455 |78W-I |NCITR* ← 頭字語 11) | | |g/kg | |NCI-TR-2, | | | | |1976 -----------+----------+--------+-----------+---------+----------- : 省略
TUMORIGENIC DATA REFERENCES: ← 表示形式に FULL をつけると出典の詳細も表示される INHEAO Industrial Health (National Institute of Industrial Health, 6-21-1 Nagao, Tama-ku, Kawasaki, 213 Japan) V.1- 1963- NCITR* National Cancer Institute Carcinogenesis Technical Report Series (Bethesda, MD) No.0-205. For publisher information, see NTPTR*. : 省略

注 8)
TUM フィールドでは,投与された物質の総量

注 9)
投与期間 (Duration:DUR) フィールドのコード類の意味は以下のとおり.
- S : Second - M : Minute - H : hour - D : Day - Y : Year
- W : Week - C : Continuous - I : Intermittent

注 10)
出典情報 (Source:SO) フィールドの 6 文字コードは CODEN で,"CODEN,巻または号,記事の開始ページ,出版年 (2 桁)" の形式で入力されている.

例 : INHEAO ← Industrial Health の CODEN
21,243,83 ← 第 21 巻,243 ページから始まる記事,1983 年出版

注 11)
CODEN が不明の文献に対しては,4 桁または 5 桁で出版物のタイトルの頭字語を表し,最の 2 桁または 3 桁にアスタリスクが付与されている.

● レビュー類に関するサンプルレコードとその見方

=> D BIB   ← レビュー類をまとめて表示する  
 
L1 ANSWER 1 of 1 RTECS COPYRIGHT 2002 DOC
CANCER REVIEW (CREV): ← 癌レビュー 12) IARC Cancer Review:Animal Limited Evidence IMEMDT 20,545,1979
CANCER REVIEW (CREV): IARC Cancer Review:Human Limited Evidence IMEMDT 63,75,1995
CANCER REVIEW (CREV): IARC Cancer Review:Human Inadequate Evidence IMEMDT 20,545,1979 : 省略 CANCER REVIEW (CREV): IARC Cancer Review:Group 2A IMEMDT 63,75,1995
TOXICOLOGY REVIEW (TREV): ← 毒物学レビュー 13) TOXICOLOGY REVIEW JTEHD6 2,671,1977 : 省略 THRESHOLD LIMIT VALUE (TLV): ← 限界値 14) ACGIH TLV-STEL 100 ppm DTLVS* TLV/BEI,1999
THRESHOLD LIMIT VALUE (TLV): ACGIH TLV-TWA 50 ppm DTLVS* TLV/BEI,1999

注 12)
IARC (International Agency for Research on Cancer) では発癌性の疑いがある物質を試験し,その結果と適切な文献情報をモノグラフにまとめている.結果は以下のコードで表されている.

 - ANIMAL SUFFICIENT EVIDENCE      - HUMAN SUFFICIENT EVIDENCE
- ANIMAL LIMITED EVIDENCE - HUMAN LIMITED EVIDENCE
- ANIMAL INADEQUATE EVIDENCE - HUMAN INADEQUATE EVIDENCE
- ANIMAL NO EVIDENCE - HUMAN NO EVIDENCE
- GROUP 1:人間に対しては,発癌性があると IARC は認めた.
- GROUP 2:人間に対しては,恐らく発癌性があると IARC は認めた.
- GROUP 3:人間に対する発癌物質とは分類できないと IARC は認めた.
- GROUP 4:人間に対しては,恐らく発癌性はないと IARC は認めた.

注 13)
レビューの書誌情報が収録されている.ほとんどの文献には特定の用量の数値データが記載されていない.

注 14)
ACGIH (American Conference of Governmental Industrial Hygienists) が勧告している値暴露してもほとんどの労働者に有害作用が現れない限界値.
- TWA (time-weighted average):一日 8 時間,週に 40 時間労働時の限界濃度
- STEL (short term exposure limit):15 分以内の暴露限界濃度.ただし,少なくとも 60
分の間隔をあけて一日に 4 回までの制限があり,一日の TWA を越えてはならない.
- CL (ceiling value):一瞬でも越えてはならない暴露限界濃度

● 規制情報に関するサンプルレコードとその見方

=> D LEGAL    ← 規制情報をまとめて表示する
 
L1 ANSWER 1 of 1 RTECS COPYRIGHT 2002 DOC
STANDARDS AND REGULATIONS (SREG): ← 規制および基準 15) MSHA STANDARD-air:TWA 100 ppm (535 mg/m3) DTLVS* 3,263,1971
STANDARDS AND REGULATIONS (SREG): OSHA PEL (Gen Indu):8H TWA 100 ppm;CL 200;Pk 300/5M/2H CFRGBR 29,1910.1000,1994 ← CFR のセクション番号 : 省略
STANDARDS AND REGULATIONS (SREG): ← フランスの暴露基準 OEL-FRANCE: VME 75 ppm (405 mg/m3), VLE 200 ppm (1080 mg/m3), C3 Carci nogen, JAN1999
STANDARDS AND REGULATIONS (SREG): ← ドイツの暴露基準 OEL-GERMANY: MAK 50 ppm (270 mg/m3), Carcinogen, JAN1999
STANDARDS AND REGULATIONS (SREG): ← ハンガリーの暴露基準 OEL-HUNGARY: TWA 10 mg/m3, STEL 40 mg/m3, JAN1993
STANDARDS AND REGULATIONS (SREG): ← 日本の暴露基準 OEL-JAPAN: OEL 50 ppm (270 mg/m3), 2B Carcinogen, JAN1999 : 省略
NIOSH RECOMMENDATIONS (NREC): ← NIOSH 勧告 16) NIOSH REL TO TRICHLOROETHYLENE-air:10H CA TWA 25 ppm;CL 2 ppm/1H NIOSH* DHHS #92-100,1992
NIOSH RECOMMENDATIONS (NREC): NIOSH REL TO WASTE ANESTHETIC GASES AND VAPORS-air:CL 2 ppm/1H MMWR** 37(S-7),28,1988 : 省略

注 15)
以下の政府機関または法律などによる規制状況がコードで表されている.
- DOT (または IMO) : Department of Transportation
- MSHA : the Federal Mine Safety and Health Act
- OSHA PEL : Occupational Safety and Health Administration の Permissible
Exposure Limit
- OEL : the Occupational Exposure Limits (米国以外の暴露基準)
- EPA FIFRA : Environmental Protection Agency の Federal Intecticide,
Fungicide, and Rodenticide Act

注 16)
REL (Recommended Exposure Levels) は NIOSH の the Standards Development Program が作成する,職場での暴露基準.

- NIOSH : National Institute for Occupational Safety and Health

NATIONAL OCCUPATIONAL SURVEY (SURV): ← 全国職業調査 17)
NOHS 1974: HZD 73790; NIS 251; TNF 37699; NOS 141; TNE 446588

NATIONAL OCCUPATIONAL SURVEY (SURV):
NOES 1983: HZD 73790; NIS 192; TNF 23225; NOS 143; TNE 401373; TFE 175316

FEDERAL AGENCY STATUS (ASTA): ← 機関識別 18)
ATSDR TOXICOLOGY PROFILE (NTIS** PB/90/127523/AS)

FEDERAL AGENCY STATUS (ASTA):
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-RLV F344 rat embryo;
Host-mediated assay
: 省略
FEDERAL AGENCY STATUS (ASTA):
NCI Carcinogenesis Bioassay (gavage);clear evidence:mouse NCITR*
NCI-TR-2,1976

FEDERAL AGENCY STATUS (ASTA):
NTP Carcinogenesis Studies (gavage);clear evidence:mouse NTPTR*
NTP-TR-243,1983
: 省略
FEDERAL AGENCY STATUS (ASTA):
NTP 9th Report on Carcinogens,2000:Reasonably anticipated to be human
Carcinogen

注 17)
米国の産業界を対象に 2 回にわたって行った NIOSH の全国調査の結果.職場における暴露の可能性がコードで表されている.

- NOHS : the National Occupational Hazard Survey (1972-74 施行)
- NOES : the National Occupational Exposure Survey (1980-83 施行)
- HZD : Hazard Number (Internal number used by NIOSH)
- NIS : Number of Industries Surveyed
- NOS : Number of Occupations Surveyed (Uses Standard Occupation Codes)
- TFE : Total Number of Female Employees
- TNE : Total Number of Employees (estimated)
- TNF : Total Number of Facilities Surveyed

この調査の内容の詳細についての問い合わせ先:
National Institute for Occupational Safety and Health (NIOSH)
Ms Doris Sweet
4676 Columbia Parkway Cincinnati, Oh 45226
(513) 533-8359

注 18)
以下の政府機関が物質に対して行っている活動について,まとめられている.
- ATSDR:The Agency for Toxic Substances and Disease Registry
- EPA :Environmental Protection Agency
- NIOSH:National Institute for Occupational Safety and Health
- NTP :National Toxicology
- NCI :National Cancer Institute